Please wait while the formulary information is being retrieved.
BELEODAQ (belinostat)
- Peripheral t-cell lymphoma
500 mg intravenous solution
- Infuse 1,000 mg/m2 over 30 minute(s) by intravenous route once daily on days 1 through 5 of a 21 day treatment cycle
Peripheral t-cell lymphoma
- Infuse 1,000 mg/m2 over 30 minute(s) by intravenous route once daily on days 1 through 5 of a 21 day treatment cycle
- Infuse 750 mg/m2 over 30 minute(s) by intravenous route once daily ondays 1 through 5 of a 21 day treatment cycle
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- vorinostat
- Zolinza
Severe
Moderate
- None
- Lactating mother
Contraindicated
- Abnormal hepatic function tests
- Pregnancy
- Severe infection
- UGt1a1*28 polymorphism
Severe
Moderate
- Anemia
- Diarrhea
- Disease of liver
- Leukopenia
- Severe renal impairment
- Thrombocytopenic disorder
- Vomiting
BELEODAQ (belinostat)
- Peripheral t-cell lymphoma
- Anemia
- Constipation
- Diarrhea
- Dyspnea
- Fatigue
- Fever
- Nausea
- Peripheral edema
- Skin rash
- Vomiting
More Frequent
Severe
Less Severe
- Hypokalemia
- Infection
- Thrombocytopenic disorder
- Acute abdominal pain
- Anorexia
- Chills
- Cough
- Dizziness
- Headache disorder
- Hypotension
- Injection site sequelae
- Phlebitis
- Pruritus of skin
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Drug-induced hepatitis
- Lymphopenia
- Neutropenic disorder
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Belinostat
Safety and efficacy not established. Pediatrics excluded from initial trials.
- 1 Day – 18 Years
- Safety and efficacy not established. Pediatrics excluded from initial trials.
Belinostat
- Severity Level:
D
- Additional Notes: Potential for serious adv effects in fetus; genotoxic to actively dividing cells
Contraindicated
Belinostat
Insufficient human data; risk of serious adverse effect due to mech of action
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Insufficient human data; risk of serious adverse effect due to mech of action |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Peripheral t-cell lymphoma | |
| C84.4 | Peripheral t-cell lymphoma, not classified |
| C84.40 | Peripheral t-cell lymphoma, not classified, unspecified site |
| C84.41 | Peripheral t-cell lymphoma, not classified, lymph nodes of head, face, and neck |
| C84.42 | Peripheral t-cell lymphoma, not classified, intrathoracic lymph nodes |
| C84.43 | Peripheral t-cell lymphoma, not classified, intra-abdominal lymph nodes |
| C84.44 | Peripheral t-cell lymphoma, not classified, lymph nodes of axilla and upper limb |
| C84.45 | Peripheral t-cell lymphoma, not classified, lymph nodes of inguinal region and lower limb |
| C84.46 | Peripheral t-cell lymphoma, not classified, intrapelvic lymph nodes |
| C84.47 | Peripheral t-cell lymphoma, not classified, spleen |
| C84.48 | Peripheral t-cell lymphoma, not classified, lymph nodes of multiple sites |
| C84.49 | Peripheral t-cell lymphoma, not classified, extranodal and solid organ sites |
| 0-9 | A-Z |
|---|---|
| C84.4 | Peripheral t-cell lymphoma, not classified |
| C84.40 | Peripheral t-cell lymphoma, not classified, unspecified site |
| C84.41 | Peripheral t-cell lymphoma, not classified, lymph nodes of head, face, and neck |
| C84.42 | Peripheral t-cell lymphoma, not classified, intrathoracic lymph nodes |
| C84.43 | Peripheral t-cell lymphoma, not classified, intra-abdominal lymph nodes |
| C84.44 | Peripheral t-cell lymphoma, not classified, lymph nodes of axilla and upper limb |
| C84.45 | Peripheral t-cell lymphoma, not classified, lymph nodes of inguinal region and lower limb |
| C84.46 | Peripheral t-cell lymphoma, not classified, intrapelvic lymph nodes |
| C84.47 | Peripheral t-cell lymphoma, not classified, spleen |
| C84.48 | Peripheral t-cell lymphoma, not classified, lymph nodes of multiple sites |
| C84.49 | Peripheral t-cell lymphoma, not classified, extranodal and solid organ sites |
Formulary Reference Tool